Catalyst
Slingshot members are tracking this event:
Allergan's Rapastinel Receives FDA Breakthrough Therapy Designation for Adjunctive Treatment of Major Depressive Disorder
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| AGN |
|
|
||||
Additional Information
The Breakthrough Therapy designation was based on preclinical and preliminary clinical evidence for rapastinel, which supports a rapid (within 1 day) and sustained antidepressant effect over the course of the Phase II studies. Rapastinel has been found to be well tolerated in studies to date, with no psychotomimetic or hallucinogenic side effects observed.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Jan 29, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Rapastinel, Breakthrough Therapy Designation, Fda, Major Depressive Disorder
